Participants receiving a histologic diagnosis of epithelial ovarian cancer (EOC), peritoneal primary carcinoma, or fallopian tube cancer
Have recurrent invasive epithelial ovarian, fallopian tube, or primary peritoneal cancer that was treated only with surgery (example [e.g.], participants with Stage IA or Stage IB epithelial ovarian or fallopian tube cancers)
Patients must have a histological or cytological evidence/confirmation of epithelial ovarian cancer, primary peritoneal carcinomatosis, or fallopian tube cancer
Have a diagnosis of advanced platinum resistant epithelial ovarian cancer (EOC)/fallopian tube cancer/primary peritoneal cancer (PPC)  Up to - prior lines of therapy
Histologically or cytologically confirmed advanced ovarian cancer: epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer (excluding borderline ovarian cancer) that is resistant or refractory to platinum therapy and no other standard therapy with proven clinical benefit is available.
Histological diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer, excluding the mucinous subtype.
Patients who have received any targeted therapy (including but not limited to vaccines, antibodies, tyrosine kinase inhibitors) or hormonal therapy for management of their epithelial ovarian, fallopian tube or peritoneal primary cancer
Histologically confirmed stage IIc-IV epithelial ovarian, fallopian tube or peritoneal cancer
Epithelial ovarian carcinoma (including primary peritoneal disease and/or fallopian tube carcinomas and/or endometrial adenocarcinomas) regardless of platinum sensitivity.
For cohorts -,  and : patients must have breast and/or epithelial or endometrioid ovarian cancer, primary peritoneal cancer, and/or fallopian tube cancer histologically or cytologically confirmed at the National Cancer Institute (NCI) that is metastatic or unresectable and for which standard curative measures do not exist or are no longer effective; ER/PR/HER status needs to be documented either by an outside source or at NCI; patients with gBRCA/m with history of or active breast and ovarian cancers are considered for cohort ; those without gBRCA/m will follow exclusion criteria
STUDY ENTRY: No prior treatment for primary advanced (stage III or IV) epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.
GENERAL: Prior systemic chemotherapy for epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Ovarian Expansion Cohort: Subjects with recurrent disease or histologically or cytologically confirmed Stage III/IV diagnosis of epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal carcinoma who have previously progressed while receiving or within  months of completing a platinum-containing regimen.
Subjects must have histologically or cytologically confirmed advanced epithelial ovarian, fallopian tube, or primary peritoneal (>= International Federation of Gynecology and Obstetrics [FIGO] Stage IIIC)
Patients with a histologic diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, stage IIIB  IIIC with optimal (=<  cm) residual disease
Histologic diagnosis of recurrent epithelial ovarian, fallopian, peritoneal cancer
Patients who have received any prior treatment for management of their epithelial ovarian, fallopian tube or peritoneal primary cancer
Patients must have histologically or cytologically confirmed non-mucinous, epithelial stage  or  carcinoma of the ovary, fallopian tube or peritoneum
Histology (reviewed at MD Anderson Cancer Center [MDACC]) showing recurrent high grade epithelial ovarian, peritoneal, or fallopian tube cancer.
Patients must have histologically or cytologically confirmed advanced metastatic or unresectable epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer that is relapsed and resistant (recurred less than  months after chemotherapy) or refractory (progressed on chemotherapy) to prior platinum- and taxane-based standard care systemic regimen; or patients who are not eligible for additional platinum therapy; histopathologic diagnosis must be confirmed in the laboratory of pathology (LP), National Cancer Institute (NCI)
Histologically confirmed stage III-IV high-grade epithelial non-mucinous ovarian, fallopian tube, or primary peritoneal cancers
Patients must have histologically confirmed endometrial cancer, epithelial ovarian, fallopian tube, or primary peritoneal cancer (all histologic subtypes)
Have histologically or cytologically confirmed gynecologic tumor of mullerian origin, specifically epithelial ovarian, fallopian tube, primary peritoneal, or uterine endometrial cancer
Histology showing high-grade epithelial non-mucinous ovarian, primary peritoneal, or fallopian tube cancer
No prior treatment for primary advanced (stage III or IV) epithelial ovarian, primary peritoneal, or fallopian tube carcinoma such as irradiation, chemotherapy, hormonal therapy, immunotherapy, investigational therapy, surgery, and/or other concurrent agents or therapies
Patients with histologic diagnosis of epithelial ovarian carcinoma, primary peritoneal carcinoma, or fallopian tube carcinoma that has recurred >  months since platinum-based chemotherapy (first recurrence) and who are scheduled for secondary surgical evaluation/cytoreduction
Histologically confirmed epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
Patients with histologically or cytologically confirmed diagnosis of advanced, epithelial ovarian cancer (except carcinosarcoma), primary peritoneal, or fallopian tube cancer who have all of the following:
Newly diagnosed advanced (FIGO stage III-IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Subjects with locally invasive or metastatic, epithelial ovarian, fallopian tube, or primary peritoneal cancer
Histologically confirmed recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer for which there is no known or established treatment available with curative intent.
Patients with biopsy-confirmed ovarian or other gynecologic cancers (fallopian tube, peritoneal, endometrial, or cervical cancer) who have recurred after or progressed on frontline and one or more second-line standard treatments are eligible for the dose-finding phase; enrollment for the expansion cohort will be limited to subjects with high grade epithelial ovarian, fallopian tube, or peritoneal carcinomas
Histology showing recurrent high grade epithelial ovarian, peritoneal, or fallopian tube cancer
Diagnosis of recurrent epithelial ovarian cancer, fallopian tube, or primary peritoneal cancer that has failed or progressed after at least  prior salvage chemotherapy regimen directed at recurrent/metastatic disease
Participants must have pathology-confirmed epithelial ovarian, fallopian tube, or\n             primary peritoneal carcinoma.
Participants with histologically or cytologically confirmed diagnosis of epithelial ovarian, primary peritoneal or fallopian tube cancer will be enrolled in this study; patients must have experienced recurrence or progression within  months after completion of platinum based chemotherapy (by Response Evaluation Criteria in Solid Tumors [RECIST] . criteria).
Newly diagnosed stage III or IV epithelial ovarian, fallopian or primary peritoneal carcinoma with or without ascites and potentially resectable disease agreeing to debulking surgery as standard therapy
Patients who have had prior systemic therapy or radiotherapy for stage III or IV epithelial ovarian, fallopian or primary peritoneal carcinoma
Patients with a histologic diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, or carcinosarcoma stage II, III, or IV with either optimal (=<  cm residual disease) or suboptimal residual disease
All patients must have a procedure for determining diagnosis of epithelial ovarian, fallopian tube, primary peritoneal, or carcinosarcoma with appropriate tissue for histologic evaluation
Patients with a current diagnosis of borderline epithelial ovarian tumor (formerly tumors of low malignant potential) or recurrent invasive epithelial ovarian, primary peritoneal or fallopian tube cancer treated with surgery only (such as patients with stage IA or IB low-grade epithelial ovarian or fallopian tube cancers) are not eligible\r\n* NOTE: Patients with a prior diagnosis of a borderline tumor that was surgically resected and who subsequently develop an unrelated, new invasive epithelial ovarian, peritoneal primary or fallopian tube cancer are eligible, provided that they have not received prior chemotherapy for any ovarian tumor
Histologic diagnosis of International Federation of Gynecology and Obstetrics (FIGO) Stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal carcinoma, with the appropriate tissue available for histologic evaluation.
Diagnosed with advanced epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer
Patients must have histologic diagnosis of epithelial ovarian carcinoma, peritoneal primary or fallopian tube carcinoma, which is now recurrent
Histologically proven advanced-relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer
Patients with recurrent epithelial ovarian cancer, fallopian tube cancers or primary peritoneal carcinoma defined as:
epithelial ovarian cancer (fallopian tube and primary peritoneal cancers are eligible)
Has histologically confirmed epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer
Ovarian cancer defined as a histologically confirmed diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal cancer refractory to standard therapies of for which no standard therapy exists. Confirmed BRCA or BRCA mutation from a prior test. Patient progressed while receiving and/or following treatment with a PARP-inhibitor for advanced disease (recurrent or metastatic.
The patient must have a pathologically confirmed (by histology or cytology) diagnosis of epithelial ovarian, fallopian tube or primary peritoneal carcinoma, which is currently recurrent or persistent Stage  or Stage  disease. A histologic diagnosis of borderline, low malignant potential epithelial carcinoma is not permitted.
Have a histologically confirmed diagnosis of epithelial ovarian cancer, fallopian tube or peritoneal cancer; all histologies of epithelial ovarian cancer are eligible except for carcinosarcomas
Histologically confirmed ovarian epithelial (including fallopian tube and primary peritoneal) carcinoma.
Patients with recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
Confirmed diagnosis of unresectable epithelial ovarian, fallopian tube or primary peritoneal cancer.
Patients are eligible if they have the following: metastatic or unresectable breast cancer, recurrent or persistent epithelial ovarian, fallopian tube, or primary peritoneal cancer
Histologically confirmed epithelial ovarian, primary peritoneal or fallopian tube malignancy that is metastatic and for which standard curative measures do not exist
Must have a diagnosis of recurrent epithelial ovarian, primary peritoneal or fallopian tube carcinoma with refractory or platinum resistant disease and/or have received ?  lines of chemotherapy
Histologically-confirmed ovarian epithelial (including fallopian tube and primary peritoneal) carcinoma
Patients assumed to have a stageII?IV epithelial ovarian, fallopian tube, or primary peritoneal cancer as a pre-surgery diagnosis
Patients with non-epithelial ovarian tumors that do not require adjuvant chemotherapy, borderline epithelial ovarian tumor, or recurrent invasive epithelial ovarian, low grade ovarian cancer, primary peritoneal, or fallopian tube cancer treated with surgery only (such as patients with stage IA or IB); patients with a prior diagnosis of a borderline tumor that was surgically resected and who subsequently develop an unrelated new invasive epithelial ovarian, primary peritoneal, or fallopian tube cancer are eligible, provided that they have not received chemotherapy for any tumor; no stromal cancers or germ cell cancers or low malignant potential; patients found post operatively to have ineligible histology will be removed from the study
Have a histologically confirmed diagnosis of high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer
PHASE I: Participants must have histologically or cytologically confirmed epithelial ovarian cancer, primary peritoneal serous cancer, fallopian tube cancer, or triple-negative breast cancer
PHASE I-T: Participants must have histologically or cytologically confirmed epithelial ovarian cancer, primary peritoneal serous cancer, or fallopian tube cancer
Patients with borderline epithelial ovarian tumor (formerly \tumors of low malignant potential\) or recurrent invasive epithelial ovarian, primary peritoneal or fallopian tube cancer treated with surgery only are not eligible. Patients with a prior diagnosis of a borderline tumor that was surgically resected and who subsequently develop an unrelated, new invasive epithelial ovarian, peritoneal primary or fallopian tube cancer are eligible, provided that they have not received prior chemotherapy for any ovarian tumor.
Histologically or cytologically confirmed epithelial ovarian, fallopian tube, or peritoneal cancer
Histological documentation of epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer
Part  (enrollment closed): advanced, metastatic or non-resectable epithelial ovarian cancer, primary peritoneal cancer or fallopian tube cancer with
Histologically documented epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer that is platinum sensitive.
PSOC (i.e., epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer) with documented radiographic progression or relapse within  to  months of most recent platinum-based chemotherapy.
Histologic diagnosis of epithelial ovarian, fallopian tube or primary peritoneal cancer on frozen section diagnosis
Patients must have newly diagnosed International Federation of Gynecology and Obstetrics (FIGO) Stage IIIB to IV epithelial ovarian, fallopian tube, or peritoneal cancer and have recovered from debulking surgery.
Cytologic or histologic diagnosis of a carcinoma felt by the investigator to be compatible with epithelial cancer of the ovary, fallopian tube, or primary peritoneum
Diagnosis of ovarian epithelial, fallopian tube, or primary peritoneal carcinoma\r\n* Stage II, III, or IV disease with optimal (=<  cm residual disease) or suboptimal residual disease\r\n* All patients must have a procedure for determining diagnosis of epithelial ovarian, fallopian tube, primary peritoneal, with appropriate tissue for histologic evaluation\r\n* The minimum surgery required is an abdominal surgery providing tissue for histologic evaluation and establishing and documenting the primary site and stage, as well as a maximal effort at tumor debulking; if additional surgery was performed, it should have been in accordance with appropriate surgery for ovarian or peritoneal carcinoma described in the Gynecologic Oncology Group (GOG) Surgical Procedures Manual
Diagnosed with advanced epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer
Histology showing high-grade epithelial non-mucinous ovarian, primary peritoneal, or fallopian tube cancer
No more than  prior cycles of chemotherapy for primary advanced (stage III or IV) epithelial ovarian, primary peritoneal, or fallopian tube cancer
Patients with a histological diagnosis of epithelial ovarian cancer, fallopian tube or primary peritoneal carcinoma, clinical stage II, III or IV at diagnosis
Patients with a histological diagnosis of clinical stage I epithelial ovarian cancer, fallopian tube or primary peritoneal carcinoma
Adult patients who have a presumed diagnosis of advanced stage epithelial ovarian, fallopian tube, or peritoneal\r\n* Pelvic mass and/or omental caking with Ca-:carcinoembryonic antigen (CEA) ratio :
Histologic diagnosis of epithelial ovarian, fallopian tube or primary peritoneal cancer confirmed on frozen section diagnosis during debulking surgery
Epithelial ovarian cancer (including primary peritoneal disease and/or fallopian tube carcinomas and/or endometrial adenocarcinomas).
Have a primary diagnosis, or at high clinical suspicion, of primary ovarian cancer (of epithelial type), planned for primary debulking or interval debulking surgery, and:
